Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Oct 29;3(10):e144. doi: 10.1038/psp.2014.42

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 American Society for Clinical Pharmacology and Therapeutics

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

PMC Copyright notice

Model-based simulations by diagnosis. Each patient from the analysis data set was used to create 100 simulated patients with the same covariates but different individual random effects. Concentration–time courses were simulated following 1,000 mg intravenous doses of obinutuzumab on days 1, 8, 15 of cycle 1, and day 1 of cycles 2–6. Residual variability was included. Once-a-day sampling was assumed. Medians (red) and 5th and 95th percentiles (blue) of the simulated concentrations are plotted. BCL, B-cell lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma.